DNTH Stock Forecast & Price Target

Dianthus Therapeutics is viewed positively because it combines a substantial cash position of approximately $887M at the end of 2Q26 with expected near-term milestone payments, giving management confidence in funding planned operations into 2030 and reducing near-term financing risk despite the company’s clinical-stage profile. Its lead programs continue to advance with important catalysts, including Phase 2 MoMeNtum top-line data in 46 patients on track for December 2026, the anticipated Phase 3 gMG study start by mid-2026, and the expansion of DNTH212 into Sjögren’s Disease, SLE, and dermatomyositis, which together represent an estimated ~625,000 U.S. patients. The bullish case is further supported by classeprubart’s positioning as a potentially more potent, next-generation complement therapeutic administered subcutaneously every 2 weeks, alongside favorable early comparator data in the broader complement space and a large underlying market opportunity in MMN of approximately 10,000 U.S. patients.

Dianthus Therapeutics is a clinical-stage biotech with no approved products yet, so its valuation rests almost entirely on execution across a concentrated, high-risk pipeline rather than recurring commercial cash flow. The key fundamental concern is that management pushed the claseprubart Phase 2 MMN study to 4Q26 from 2H26 and still has not provided enough detail on proof-of-concept design for DNTH212 in Sjogren's disease, SLE, and DM, leaving a meaningful evidence gap that makes the current development thesis difficult to underwrite. While claseprubart is described as more potent than empasiprubart and the CIDP read-through is encouraging, the company still needs healthy volunteer data in 2H26 and later clinical data to validate whether that potency translates into meaningful patient benefit and de-risk the pipeline.